Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

  • STATUS
    Recruiting
  • End date
    May 1, 2023
  • participants needed
    330
  • sponsor
    Sagimet Biosciences Inc.
Updated on 5 June 2021
Investigator
Study Director: Sagimet Biosciences Inc.
Primary Contact
Northeast GI Research Division (6.2 mi away) Contact
+65 other location

Summary

This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH). Subjects will be randomly assigned toTVB-2640 or matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.

Details
Condition NAFLD, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease, non-alcoholic fatty liver
Treatment Placebo, TVB-2640
Clinical Study IdentifierNCT04906421
SponsorSagimet Biosciences Inc.
Last Modified on5 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Must be willing and able to participate in the study and provide written informed consent
Male and female adults 18 years of age on the date that written informed consent to take part in the study is provided
Body mass index (BMI) 23 kg/m2 and <40 kg/m2 for Asians and 25 kg/m2 and <40 kg/m2 for other races
Female subjects must be either
Not of childbearing potential OR
Women of childbearing potential (WOCBP) must have a negative serum pregnancy (beta-human chorionic gonadotropin [-HCG]) test during Screening, a negative urine pregnancy test within 24 hours before the first dose of study drug on Day 1, and must agree to perform urine home pregnancy tests monthly between study visits. WOCBP must not be breastfeeding, not plan to become pregnant during the study, and must use birth control
Must have confirmation of 8% liver fat content by MRI-PDFF during the Screening period
Histologic confirmation of NASH: must have had prior liver biopsy within 180 days before randomization (randomization is within 24 hours of Baseline [Day1]) with fibrosis stage F2-F3 and a NAS of 4

Exclusion Criteria

History of harmful alcohol intake for a period of more than 3 consecutive months within 1 year prior to Screening in the judgement of the Investigator
Active substance abuse
Gain or loss of >5% of body weight in the 6 months prior to Baseline (Day 1) or >10% of body weight in the 12 months prior to Screening
Type 1 diabetes mellitus by history
Positive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR) test within 30 days before Baseline, history of hospitalization for coronavirus disease-2019 (COVID-19), or history of use of oxygen due to COVID-19. Note that previous COVID-19 infection alone is not exclusionary and vaccination against SARS-CoV-2 is allowed, but must be documented
Uncontrolled T2DM, defined as HbA1c 9% at Screening (subjects with HbA1c 9% may be rescreened on 1 occasion only at the Investigator's discretion)
Presence of cirrhosis on liver histology (stage 4 fibrosis), according to the judgement of the central reader, and/or cross sectional
Use of glucagon-like peptide-1 (GLP-1) agonists, unless on a stable daily dose for at least 6 months prior to the Screening visit date, or on a complex oral anti-diabetic (OAD) regimen (3 or more OADs), unless on a stable dose for at least 6 months prior to the Screening visit date
Subjects with active or quiescent chronic liver disease of etiologies other than NASH (eg, viral or autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, and 'autoimmune hepatitis-overlap' syndromes, hemochromatosis, Wilson's disease, alpha 1 antitrypsin deficiency, alcohol-related liver disease, drug-induced liver disease, and/or infiltrative conditions [eg, sarcoidosis])
Current or historic clinically evident hepatic decompensation event (eg, ascites formation, variceal hemorrhage, hepatic encephalopathy)
Any subject who has sustained a clinically evident cardiovascular, cerebrovascular, and/or peripheral vascular event during the 12 months prior to anticipated Baseline (Day 1) visit date is not eligible for study participation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note